Results From Phase 2 Clinical Study of 6R-BH4 in Peripheral Arterial Disease Not Statistically Significant
In February 2009, BioMarin announced results from its Phase 2 multi-center, randomized, double-blind, placebo-controlled clinical study of 6R-BH4 in patients with symptomatic peripheral arterial disease (PAD). There was no statistical significance observed between the 6R-BH4 treatment and placebo groups. BioMarin will determine the future of its 6R-BH4 cardiovascular program following the results of additional investigator-sponsored studies of 6R-BH4 including proteinuria, pulmonary arterial hypertension and 6R-BH4 plus vitamin C in patients with endothelial dysfunction.

“The research by experts at Cardiff University’s School of Medicine has discovered that vitamin C can boost heart function by its so-called pro-oxidant effects.
Pro-oxidants are usually thought to be bad for health – they are opposite to the beneficial anti-oxidant effect which comes from a diet rich in fruit and vegetables.”

I hate when they contradict themselves especially at the beginning of the article.